Introduction

Advances in cancer genomics have significantly reshaped the understanding of tumor biology and the clinical management of malignancies. Tumors arise through the accumulation of somatic genetic alterations including point mutations, insertions and deletions, copy-number variations, and gene fusions that influence cellular signaling pathways and treatment response. The ability to identify these alterations has become central to the emerging paradigm of precision oncology.

Tumor genomic profiling refers to the systematic analysis of a tumor’s DNA (and sometimes RNA) to identify genetic alterations that may drive oncogenesis or influence therapeutic sensitivity. Using high-throughput sequencing technologies, clinicians can evaluate a tumor’s molecular landscape and potentially match patients to targeted therapies or biomarker-driven clinical trials.

Over the past decade, next-generation sequencing (NGS) technologies have enabled comprehensive genomic profiling of tumors, allowing simultaneous interrogation of multiple genes from a single specimen. This capability has transformed cancer diagnostics and treatment selection by identifying actionable genomic alterations that may guide therapy decisions.

Despite these technological advances, questions remain regarding when tumor genomic profiling should be implemented in clinical practice, which testing platforms are most appropriate, and how results should be interpreted within the broader clinical context. This article reviews the types of genomic testing available, current clinical indications, benefits and limitations, and future directions in precision oncology.

Types of Tumor Genomic Testing

Several genomic testing approaches are used in oncology. These methods differ in scope, cost, turnaround time, and clinical applicability.

Single Gene Tests

Historically, molecular diagnostics in oncology focused on single-gene assays designed to detect specific mutations associated with targeted therapies. Examples include testing for EGFR mutations in non-small cell lung cancer or BRAF V600E mutations in melanoma.

Single-gene tests remain clinically relevant when a specific biomarker is strongly associated with a targeted therapy and when guidelines recommend testing for that mutation. These assays typically use polymerase chain reaction (PCR) or focused sequencing methods and offer rapid turnaround times.

However, as the number of actionable biomarkers has increased, single-gene testing can become inefficient because multiple assays may be required to evaluate all relevant genomic alterations.

Next-Generation Sequencing Panels

Next-generation sequencing (NGS) panels have become the most widely used genomic profiling approach in clinical oncology. These panels simultaneously analyze dozens to hundreds of cancer-related genes in a single assay.

NGS panels offer several advantages:

• Detection of multiple mutation types (single nucleotide variants, insertions/deletions, copy-number alterations, and gene fusions)

• Efficient use of limited tumor tissue

• Ability to identify actionable genomic alterations associated with targeted therapies or clinical trials
  

Clinical guidelines increasingly recommend NGS testing in certain cancers with multiple relevant biomarkers, including lung, ovarian, prostate, and cholangiocarcinoma.

As precision oncology expands, NGS panels have become central to identifying molecular drivers of disease and selecting biomarker-driven therapies.

Whole Genome Sequencing

Whole genome sequencing (WGS) provides the most comprehensive view of tumor genetics by sequencing the entire genome of cancer cells. This approach can detect structural variations, complex genomic rearrangements, and noncoding mutations that may not be captured by targeted panels.

Although WGS has significant research value, its clinical use remains limited due to:

• High cost and computational requirements

• Longer turnaround times

• Uncertain clinical interpretation of many detected variants

Nonetheless, large-scale sequencing initiatives and translational research studies are increasingly exploring WGS to uncover novel therapeutic targets and improve molecular classification of tumors.

Clinical Indications for Tumor Genomic Profiling

While genomic testing has broad potential applications, its use should be guided by clinical context and evidence-based recommendations.

Metastatic or Advanced Cancers

The strongest evidence supporting genomic profiling exists in metastatic or advanced cancers, where standard treatment options may be limited.

Professional societies such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommend genomic testing in patients with metastatic disease when targeted therapies linked to specific genomic alterations are available.

Examples include:

• Non–small cell lung cancer

• Ovarian cancer

• Prostate cancer

• Cholangiocarcinoma
  

In these settings, identifying actionable alterations can directly inform treatment selection.

Evidence from clinical studies suggests that comprehensive genomic profiling can identify potentially actionable alterations in a substantial proportion of patients with metastatic tumors.

Rare Tumors

Genomic profiling may also be valuable in rare cancers, where limited clinical trial data or therapeutic guidelines exist.

Rare tumors often harbor unique genomic alterations that may guide targeted therapy or enrollment in basket trials investigating drugs across tumor types with shared molecular features.

Furthermore, tumor-agnostic therapies, such as drugs targeting specific genomic alterations regardless of tumor origin, have expanded the role of genomic profiling in rare cancers.

Therapy-Resistant Disease

Genomic profiling can also be useful in patients with treatment-resistant cancers.

Resistance to targeted therapies or cytotoxic agents frequently arises from secondary mutations or alternative pathway activation. Sequencing tumor samples after disease progression may reveal new therapeutic targets or resistance mechanisms.

For example, detection of secondary mutations in kinase domains or pathway alterations may guide selection of next-line targeted therapies or clinical trials.

Benefits of Tumor Genomic Profiling

Identifying Actionable Mutations

One of the primary clinical benefits of tumor genomic profiling is the identification of actionable genomic alterations mutations associated with approved targeted therapies or investigational drugs.

These alterations can include:

• Oncogenic driver mutations

• Gene amplifications

• Gene fusions

• Genomic signatures such as tumor mutational burden
  
  

By linking molecular alterations to therapeutic options, genomic profiling enables more precise treatment selection and may improve outcomes for selected patient populations.

Precision oncology frameworks, such as knowledge bases that link genomic alterations to therapeutic evidence levels, are increasingly used to interpret sequencing results and guide clinical decisions.

Eligibility for Clinical Trials

Genomic profiling also facilitates patient enrollment in biomarker-driven clinical trials.

Many contemporary oncology trials use molecular eligibility criteria rather than tumor histology alone. Identifying relevant genomic alterations can allow patients to participate in targeted therapy trials or basket studies evaluating therapies across multiple tumor types.

Clinical trials remain an essential component of precision oncology because many genomic alterations lack approved therapies but may be targeted by investigational agents.

Limitations and Challenges

Despite its promise, tumor genomic profiling has several limitations that must be considered when integrating it into clinical practice.

Variants of Unknown Significance

A major challenge in genomic testing is the identification of variants of unknown significance (VUS).

These genetic alterations have uncertain clinical relevance because insufficient evidence exists linking them to tumor biology or treatment response.

The interpretation of genomic data therefore requires:

• curated knowledge bases

• multidisciplinary review through molecular tumor boards

• continuous updates as scientific evidence evolves
  

Without careful interpretation, genomic results may be difficult to translate into actionable clinical decisions.

Insurance Coverage and Cost

Another barrier to widespread adoption is cost and reimbursement.

Comprehensive genomic profiling tests may be expensive, and insurance coverage varies depending on:

• cancer type

• stage of disease

• availability of approved targeted therapies
  

In some healthcare systems, reimbursement is limited to patients with advanced or refractory disease. As a result, patients may not receive genomic testing early in the disease course, potentially missing opportunities for targeted treatment.

Evidence of Clinical Utility

Although genomic profiling can identify actionable mutations, evidence demonstrating improved clinical outcomes remains heterogeneous.

Many studies evaluating genomic-guided therapies are observational or involve small cohorts. Systematic reviews have emphasized the need for stronger evidence demonstrating improved survival, quality of life, or cost-effectiveness associated with genomic testing.

Future randomized studies and real-world evidence will be essential to clarify the clinical value of genomic profiling across different cancer types.

Implementation in Clinical Practice

Effective integration of genomic profiling into clinical oncology requires multidisciplinary collaboration.

Key components include:

• Molecular tumor boards to interpret genomic results

• standardized reporting frameworks for genomic variants

• integration of genomic data into electronic health records

• clinician education in genomic medicine
  
  

Clinical laboratories must also ensure high-quality sequencing workflows, accurate variant detection, and appropriate bioinformatics pipelines.

In addition, emerging technologies such as liquid biopsy using circulating tumor DNA (ctDNA) are expanding access to genomic profiling when tumor tissue is unavailable or when repeated sampling is required to monitor disease evolution.

Future Directions in Precision Oncology

Tumor genomic profiling is expected to play an increasingly important role in oncology as scientific knowledge and sequencing technologies continue to advance.

Several developments may shape future clinical practice:

Expanded Biomarker Discovery

Large-scale genomic datasets are improving understanding of tumor heterogeneity and revealing new molecular drivers of cancer.

Tumor-Agnostic Therapies

The approval of therapies targeting specific genomic alterations regardless of tumor type may broaden indications for genomic profiling.

Integration with Other Omics Data

Future precision oncology approaches may combine:

• genomic data

• transcriptomics

• proteomics

• epigenetic profiling
  

to better characterize tumor biology and guide treatment.

Artificial Intelligence and Decision Support

Machine learning tools are being developed to assist clinicians in interpreting complex genomic datasets and matching patients to therapies or clinical trials.

Conclusion

Tumor genomic profiling represents a foundational component of precision oncology. Advances in sequencing technologies particularly next-generation sequencing have enabled comprehensive analysis of tumor genetics and expanded opportunities for biomarker-driven treatment.

Current evidence supports the use of genomic profiling in metastatic cancers, rare tumors, and therapy-resistant disease, where identifying actionable mutations may inform treatment decisions or clinical trial participation. However, challenges remain, including interpretation of variants of unknown significance, variable insurance coverage, and limited evidence demonstrating improved outcomes in some clinical contexts.

As genomic technologies continue to evolve, integrating tumor genomic profiling into routine oncology practice will require careful evaluation of clinical utility, cost-effectiveness, and implementation strategies. Ongoing research and collaborative initiatives will be essential to ensure that genomic insights translate into meaningful improvements in patient care.